Clinical Trials on Pituitary Disorders

Total 144401 results

Ipsen

Terminated

Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly (DOPAACRO 002)

Acromegaly

Serbia, Belgium, Hungary, Ukraine
Ipsen

Completed

Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery (ESPORA)

Acromegaly

Spain
Ipsen

Terminated

Predictive Factors Study (TAPAS)

Acromegaly

Australia
Ipsen

Completed

One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma

Acromegaly

United Kingdom, France, Italy, Czechia, Germany, Turkey
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

Acromegaly

United States, Germany, Italy, Belgium, Taiwan, Turkey, Switzerland, Israel, Netherlands, Sweden, United Kingdom, Korea, Republic of, Spain, France, Canada, Greece, Russian Federation, Denmark, Mexico, China, Hungary, Norway, Argentina and more
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients (HOSCAR)

Acromegaly

Italy, France, Portugal, Poland, Switzerland
University of Aarhus
Odense University Hospital; Aarhus University Hospital; Herlev Hospital; Aalborg... and other collaborators

Completed

Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target

Acromegaly

Denmark
Erasmus Medical Center
Novartis

Unknown

Pasireotide LAR and Pegvisomant Study in Acromegaly (PAPE)

Acromegaly

Netherlands
Italfarmaco

Completed

Phase II Study With ITF2984 in Acromegalic Patients (POC)

Acromegaly

France, Hungary, Netherlands, Serbia, Czech Republic, Italy, Spain, Poland, Romania
Rigshospitalet, Denmark

Completed

Fractionated Stereotactic Radiotherapy in Patients With Acromegaly

Acromegaly

Denmark
TC Erciyes University

Unknown

Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly (AIP)

Acromegaly

Turkey
Endo Pharmaceuticals

Completed

Open Label Study of Octreotide Implant in Patients With Acromegaly

Acromegaly
Federal University of São Paulo

Completed

Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients

Acromegaly

Brazil
Pfizer

Completed

Non Interventional Study For Patients Treated With Somavert® (GPOS)

Acromegaly
Pfizer

Completed

Pegvisomant And Sandostatin LAR Combination Study

Acromegaly

Canada, United States, Germany, Italy, United Kingdom, Norway, Australia, Spain, Brazil, Mexico, France, Netherlands
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia

Inappropriate ADH Syndrome | Water Intoxication | Hyponatremias | Water-Electrolyte Imbalances

United States
Azienda Ospedaliero Universitaria Maggiore della...

Not yet recruiting

Hypoproteic Diet in Acromegaly (IpoProAcro)

Acromegaly

Italy
Columbia University
Ipsen

Active, not recruiting

Treatment Patterns and Treatment Outcomes for Acromegaly

Acromegaly

United States
Ipsen

Active, not recruiting

Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

Acromegaly

China
Crinetics Pharmaceuticals Inc.

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) (PATHFNDR-2)

Acromegaly

United States, Argentina, Brazil, Bulgaria, France, Hungary, Israel, Italy, Poland, United Kingdom, China, Germany, Greece, India, Spain
Pfizer

Completed

Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan

Acromegaly
Assistance Publique Hopitaux De Marseille

Completed

Late Effects of Radiosurgery on Acromegaly Study (LateRAc)

Acromegaly

France
Ionis Pharmaceuticals, Inc.

Completed

Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

Acromegaly

United States, Serbia, Poland, Russian Federation, Hungary, Lithuania
Ipsen

Withdrawn

Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China

Acromegaly
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

Acromegaly

United States, Hungary, Serbia, Romania, Russian Federation, Lithuania, Poland
Azidus Brasil

Suspended

Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®

Acromegaly

Brazil
Ipsen

Completed

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma (PRIMARYS)

Acromegaly

Netherlands, Germany, France, United Kingdom, Turkey, Belgium, Czechia, Finland, Italy
Crinetics Pharmaceuticals Inc.

Completed

An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)

Acromegaly

United States, United Kingdom, Slovakia, Australia, Italy, Hungary, Brazil, Germany, Greece, New Zealand, Poland, Romania, Serbia
Ipsen

Completed

Programme of Acromegaly Screening in Patients With Associated Somatic Disorders (ACROSCREEN)

Acromegaly

Russian Federation
Universitair Ziekenhuis Brussel

Unknown

An Assessment of the Occurrence of Hormone Deficiency in Patients With Empty Sella

Empty Sella

Belgium
Ipsen

Terminated

Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly (TULIPIA)

Acromegaly

Belgium, Brazil, Lithuania, Sweden, France, United States, Czechia, Latvia, Mexico, Netherlands, Poland, Romania, Ukraine
Ipsen

Completed

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

Acromegaly

Australia
Ipsen

Completed

Somatuline Autogel: Acromegaly Self/Partner Injection Study

Acromegaly

United Kingdom
Ipsen

Completed

Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects (SOMACROL)

Acromegaly

Spain, Portugal
Ipsen

Completed

A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide

Acromegaly

Spain, United Kingdom, Italy, France, Belgium, Hungary, Czechia, Denmark, Poland, Sweden
Ipsen

Completed

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

Acromegaly

United States, Germany, Hong Kong, Czechia, France, Hungary, Netherlands, United Kingdom
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly (LANTERN)

Acromegaly

China
Ipsen

Completed

Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly

Acromegaly

Italy
Ipsen

Completed

Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study (SODA)

Acromegaly

United States
Ipsen

Completed

Study in Polish Acromegalic Patients Treated With Somatuline Autogel

Acromegaly

Poland
Ipsen

Completed

Non Interventional Post Marketing Programme in Acromegaly

Acromegaly

United Kingdom
Cedars-Sinai Medical Center
Novartis Pharmaceuticals

Completed

Ultrasound Guided Octreotide LAR Injection in Acromegaly

Acromegaly

United States
Aspireo Pharmaceuticals Limited

Completed

Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.

Acromegaly
Aspireo Pharmaceuticals Limited

Completed

The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics

Acromegaly
Cedars-Sinai Medical Center

Completed

Tissue Biomarker for Pegvisomant Action

Acromegaly

United States
Novartis Pharmaceuticals

Completed

Octreotide Efficacy and Safety in First-line Acromegalic Patients

Acromegaly

Spain
Novartis Pharmaceuticals

Completed

Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients

Acromegaly

United States
University of Zurich

Completed

Fetal Copeptin After Oxytocin Challenge Test (CopOCT)

Pregnancy

Switzerland
University of Aarhus

Unknown

Epidemiology of Acromegaly in Denmark 1991-2010

Acromegaly

Denmark
Endo Pharmaceuticals

Terminated

Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly

Acromegaly

United States

3

Subscribe